The Senate Appropriations Committee is encouraging CMS to eliminate obstacles to biosimilar drug access to save money for Medicare Part D patients in the spending bill report it advanced this week. While unlikely to become law, the bill provides a look at policies Democrats might pursue if they control Congress in 2025. In the report on the Senate bill , released late Thursday (Aug. 1), the committee says it’s concerned about lack of access to lower-cost biosimilars for patients enrolled...